{
  "trial_id": "NCT03018080",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, ECOG performance status, ER status, PR status, HER2 status, prior lines of endocrine therapy, prior lines of chemotherapy, presence of measurable disease, absolute neutrophil count, platelet count, hemoglobin level, creatinine level, creatinine clearance, total bilirubin level, AST level, ALT level, PT, PTT, INR, pregnancy status, use of contraception, history of allergic reaction to paclitaxel, history of autoimmune disease, history of pneumonitis, history of other malignancies, HIV status, hepatitis B status, hepatitis C status, history of major surgery, history of CNS metastases, history of immunodeficiency, history of systemic steroid therapy, history of investigational agent use, history of psychiatric or substance abuse disorders, history of live vaccine administration.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "ECOG at Baseline",
          "ECOG performance status"
        ],
        [
          "Hormone Receptor Status",
          "ER status"
        ],
        [
          "Hormone Receptor Status",
          "PR status"
        ],
        [
          "Number of Prior Metastatic Chemotherapy Lines",
          "prior lines of chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Prior Paclitaxel Exposure",
        "Prior Docetaxel Exposure"
      ],
      "remaining_candidate_features": [
        "HER2 status",
        "prior lines of endocrine therapy",
        "presence of measurable disease",
        "absolute neutrophil count",
        "platelet count",
        "hemoglobin level",
        "creatinine level",
        "creatinine clearance",
        "total bilirubin level",
        "AST level",
        "ALT level",
        "PT",
        "PTT",
        "INR",
        "pregnancy status",
        "use of contraception",
        "history of allergic reaction to paclitaxel",
        "history of autoimmune disease",
        "history of pneumonitis",
        "history of other malignancies",
        "HIV status",
        "hepatitis B status",
        "hepatitis C status",
        "history of major surgery",
        "history of CNS metastases",
        "history of immunodeficiency",
        "history of systemic steroid therapy",
        "history of investigational agent use",
        "history of psychiatric or substance abuse disorders",
        "history of live vaccine administration."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, ECOG performance status, Hormone receptor status, Absolute neutrophil count, Platelet count, Hemoglobin level, Creatinine level, Creatinine clearance, Total bilirubin, AST(SGOT)/ALT(SGPT) levels, PT/PTT, INR, Prior lines of chemotherapy, Prior endocrine therapies, Metastatic sites, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "ECOG at Baseline",
          "ECOG performance status"
        ],
        [
          "Hormone Receptor Status",
          "Hormone receptor status"
        ],
        [
          "Number of Prior Metastatic Chemotherapy Lines",
          "Prior lines of chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Prior Paclitaxel Exposure",
        "Prior Docetaxel Exposure"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Absolute neutrophil count",
        "Platelet count",
        "Hemoglobin level",
        "Creatinine level",
        "Creatinine clearance",
        "Total bilirubin",
        "AST(SGOT)/ALT(SGPT) levels",
        "PT/PTT",
        "INR",
        "Prior endocrine therapies",
        "Metastatic sites"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, ER Status, PR Status, HER2 Status, Number of Prior Chemotherapy Regimens, Prior Endocrine Therapies, Prior Radiation Therapies, Measurable Disease by RECIST 1.1, Bone Disease, Hemoglobin, Absolute Neutrophil Count, Platelets, Creatinine, Total Bilirubin, AST, ALT, PT, PTT, INR.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "ECOG at Baseline",
          "ECOG Performance Status"
        ],
        [
          "Hormone Receptor Status",
          "ER Status"
        ],
        [
          "Number of Prior Metastatic Chemotherapy Lines",
          "Number of Prior Chemotherapy Regimens"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Prior Paclitaxel Exposure",
        "Prior Docetaxel Exposure"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "PR Status",
        "HER2 Status",
        "Prior Endocrine Therapies",
        "Prior Radiation Therapies",
        "Measurable Disease by RECIST 1.1",
        "Bone Disease",
        "Hemoglobin",
        "Absolute Neutrophil Count",
        "Platelets",
        "Creatinine",
        "Total Bilirubin",
        "AST",
        "ALT",
        "PT",
        "PTT",
        "INR"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, ER and PR status, HER2 status, number of prior lines of chemotherapy, presence of measurable disease, presence of evaluable bone disease, history of prior radiation therapy, history of prior anti-cancer monoclonal antibody therapy, history of prior targeted small molecule therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "ECOG at Baseline",
          "ECOG performance status"
        ],
        [
          "Hormone Receptor Status",
          "ER and PR status"
        ],
        [
          "Number of Prior Metastatic Chemotherapy Lines",
          "number of prior lines of chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment",
        "Prior Paclitaxel Exposure",
        "Prior Docetaxel Exposure"
      ],
      "remaining_candidate_features": [
        "HER2 status",
        "presence of measurable disease",
        "presence of evaluable bone disease",
        "history of prior radiation therapy",
        "history of prior anti-cancer monoclonal antibody therapy",
        "history of prior targeted small molecule therapy"
      ]
    }
  }
}